| Title | Research Team Reports Breakthrough in Pancreatic Cancer Treatment | |
| Date | Wednesday February 04, @04:34AM | |
| Author | hubie | |
| Topic | ||
| from the dept. | ||
A Spanish research team has claimed to have developed a treatment that completely eliminates the most aggressive form of pancreatic cancer in laboratory mice, raising fresh hopes against one of the deadliest cancers. Pancreatic cancer is often diagnosed late and is completely resistant to most existing treatments in later stages.
So, when Dr Mariano Barbacid claimed to have discovered a potential "cure," it sent ripples of hope across the global medical community and sparked intense scientific debate. The claim, made by the Spanish National Cancer Research Centre, working on an experimental therapy targeting the tumour cells, suggests that their approach could stop cancer growth and, in some cases, completely eliminate malignant cells in laboratory and early animal studies.
The CNIO therapy is an amalgamation of three drugs that are designed to shut down multiple tumour survival mechanisms simultaneously. According to the researchers, this strategy prevents cancer cells from rewiring themselves, a common cause of treatment failure. Dr Barbacid has previously argued that pancreatic cancer cannot be defeated with a single-drug strategy.
Given pancreatic cancer's grim statistics - five-year survival rates hovering around 10 per cent - the announcement has quickly drawn global attention.
[...] Preliminary reports say Dr Barbacid and his research team have developed a therapy that is able to disrupt the protective tumour environment, along with triggering cancer cells' death. The approach reportedly combines molecular targeting with immune system activation, which makes the tumours extremely vulnerable to treatment.
In the laboratory, according to the researchers, the therapy has been able to stop tumour progression and, in some models, even eradicate cancer cells entirely. These findings are yet to be validated in humans and could represent a major breakthrough.
However, the work is still in early stages, as many of the results so far come from preclinical studies, not large-scale human trials.
Even though the news has spread viral, cancer researchers are urging restraint, as there have been many promising cancer breakthroughs in the past which showed remarkable results in the lab but could not bring in any real-world benefits for patients in the real world.
Scientists feel that what works in animal models may not necessarily always work in humans. Also, reproducibility is another concern, as independent verification by other research groups, peer-reviewed publication, and rigorous clinical trials are essential before any treatment can be considered a true cure.
Pancreatic cancer, an announcement from Spain: "Tumor eliminated in mice":
New hope for pancreatic cancer research comes from Spain: Mariano Barbacid, director of the Experimental Oncology group at the Spanish National Cancer Research Center (CNIO), has announced the results of a mouse study demonstrating the elimination of cancer cells from the most common and devastating type of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC).
The research revealed a significant reduction in side effects from the therapy, which achieved a previously unseen duration of tumor cell elimination. "For the first time," Barbacid explained, "we have achieved a complete, durable, and low-toxicity response against pancreatic cancer in experimental models. These results indicate that the combination therapy strategy can change the course of this tumor." The oncologist presented the findings together with the study's co-author, Carmen Guerra, and the first authors, Vasiliki Liaki and Sara Barrambana, during a press conference. The study was published in PNAS (Proceedings of the National Academy of Sciences).
The key to the treatment used in the study is a combination of three drugs that target the fundamental mechanisms that allow tumor cells to grow: two targeting EGFR and STAT3, key proteins in pancreatic cancer, and one targeting the KRAS oncogene, the main driver of this tumor. Regarding next steps, Barbacid specified: "It's important to understand that, although experimental results like those described here have never been obtained before, we are not yet able to conduct clinical trials with triple therapy."
Journal Reference: https://www.pnas.org/doi/10.1073/pnas.2523039122
Original Submission #1 Original Submission #2
| Links |
printed from SoylentNews, Research Team Reports Breakthrough in Pancreatic Cancer Treatment on 2026-02-08 08:51:22